{
  "id": 15545232,
  "title": "Boryung Completes Phase 2 Trial Enrollment",
  "url": "https://urgent.news/2026/10/19/boryung-completes-phase-2-trial-enrollment",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-19T02:56:32.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=279092"
  },
  "original_language": "en",
  "account": "Boryung has finalized enrollment for Phase 2 trials of Bersomolisib (BR101801), a pioneering anticancer drug candidate that simultaneously inhibits PI3K gamma, PI3K delta, and DNA-PK. The company announced on October 19 that it had reached the target of 44 patients, seven months after the first dose in March. This rapid enrollment is notable given the challenge of recruiting participants for trials of rare blood cancers. The ongoing Phase 2 study, conducted at 17 Korean institutions, aims to assess the drug's efficacy and safety through monotherapy. Bersomolisib, a first-in-class drug, targets three pathways crucial for cancer cell growth, survival, and DNA repair. Early Phase 1 results showed promising objective responses in six out of 19 patients, with four achieving complete responses and some patients demonstrating long-term efficacy. Bersomolisib has earned orphan drug status from the U.S. FDA and Korea's Ministry of Food and Drug Safety, and has been designated as a rare disease drug in Korea, allowing conditional approval after Phase 2. Boryung aims to complete Phase 2 by 2028, following a year of post-treatment observation, with the goal of obtaining marketing authorization to expedite commercialization. The company's CEO, Kim Jeong-gyun, emphasized Bersomolisib as a testament to Boryung's research and development prowess and highlighted the drug's potential to provide a new treatment option for patients with peripheral T-cell lymphoma.",
  "summary": "Boryung has completed patient enrollment for Phase 2 clinical trials of 'Bersomolisib (BR101801),' a next-generation anticancer drug candidate that is the world's first to simultaneously inhibit PI3K gamma (γ), PI3K delta (δ), and DNA-PK, substances that cause hematologic malignancies.The company sa",
  "key_points": [
    "Boryung completes Phase 2 enrollment for Bersomolisib (44 patients)",
    "Study conducted at 17 Korean institutions, assessing efficacy and safety",
    "Bersomolisib targets three cancer cell growth pathways, orphan drug status granted"
  ],
  "editors_take": "Rapidly meeting enrollment targets for rare blood cancer trials accelerates the path toward conditional approval and commercialization for this multi-pathway anticancer drug candidate.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}